Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states

Brain

Volumn 138, Issue 1, 2015, Pages 28-35

  Little, Joshua W ^a   Ford, Amanda ^a   Symons Liguori, Ashley M ^b   Chen, Zhoumou ^a   Janes, Kali ^a   Doyle, Timothy ^a   Xie, Jennifer ^b   Luongo, Livio ^c   Tosh, Dillip K ^d   Maione, Sabatino ^c   Bannister, Kirsty ^e   Dickenson, Anthony H ^e   Vanderah, Todd W ^b   Porreca, Frank ^b   Jacobson, Kenneth A ^d   Salvemini, Daniela ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

A3AR; Adenosine; Chronic pain; Rostral ventromedial medulla; Spontaneous pain

Indexed keywords

4 AMINO 5 (3 BROMOPHENYL) 7 (6 MORPHOLINO 3 PYRIDINYL)PYRIDO[2,3 D]PYRIMIDINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ENDOCANNABINOID; MRS 5698; OPIATE; UNCLASSIFIED DRUG; 2,3-DIETHYL-4,5-DIPROPYL-6-PHENYLPYRIDINE-3-THIOCARBOXYLATE-5-CARBOXYLATE; ADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; MORPHOLINE DERIVATIVE; NALOXONE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HYPERALGESIA; MEDULLA OBLONGATA; METABOLISM; NERVE CELL; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPINAL CORD; SPRAGUE DAWLEY RAT; TIME FACTOR; TRANSGENIC MOUSE;

ADENOSINE; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYPERALGESIA; MALE; MEDULLA OBLONGATA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MORPHOLINES; NALOXONE; NEURALGIA; NEURONS; PAIN MEASUREMENT; PAIN THRESHOLD; PURINERGIC P1 RECEPTOR ANTAGONISTS; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A3; SPINAL CORD; TIME FACTORS;

EID: 84930199203     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu330     Document Type: Article

References (33)

1. 3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun 1997; 241: 297-304.
2. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107.
3. Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 2013; 65: 906-43.
4. Boison D, Chen JF, Fredholm BB. Adenosine signaling and function in glial cells. Cell Death Differ 2010; 17: 1071-82.
5. Chapman V, Suzuki R, Dickenson AH. Electrophysiological characterization of spinal neuronal response properties in anaesthetized rats after ligation of spinal nerves L5-L6. J Physiol 1998; 507 (Pt 3): 881-94.
6. 3 adenosine receptor activation. FASEB J 2012; 26: 1855-65.
7. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000; 87: 149-58.
8. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 2011; 5: 1-7.
9. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 2012; 17: 359-66.
10. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol Rev 2011; 63: 1-34.
11. Goldberg MR, Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev 1983; 35: 143-80.
12. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
13. 3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain Behav Immun 2014. Advance Access published on September 8, 2014, doi: 10.1016/j.bbi.2014.08.010.
14. Jarvis MF, Yu H, Kohlhaas K, Alexander K, Lee CH, Jiang M, et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther 2000; 295: 1156-64.
15. Jurna I. Dose-dependent inhibition by naloxone of nociceptive activity evoked in the rat thalamus. Pain 1988; 35: 349-54.
16. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63.
17. King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, et al. Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci 2009; 12: 1364-6.
18. Kowaluk EA, Mikusa J, Wismer CT, Zhu CZ, Schweitzer E, Lynch JJ, et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther 2000; 295: 1165-74.
19. Li AH, Moro S, Melman N, Ji XD, Jacobson KA. Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 1998; 41: 3186-201.
20. Little JW, Chen Z, Doyle T, Porreca F, Ghaffari M, Bryant L, et al. Supraspinal peroxynitrite modulates pain signaling by suppressing the endogenous opioid pathway. J Neurosci 2012; 32: 10797-808.
21. 3 receptors are located in neurons of the rat hippocampus. Neuroreport 2003; 14: 1645-8.
22. Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL III, et al. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res 2013; 28: 92-107.
23. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
24. Navratilova E, Xie JY, Okun A, Qu C, Eyde N, Ci S, et al. Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry. Proc Natl Acad Sci USA 2012; 109: 20709-13.
25. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010; 120: 3779-87.
26. Pizzo PA, Clark NM. Alleviating suffering 101 - pain relief in the United States. N Engl J Med 2012; 366: 197-9.
27. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, et al. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995; 56: 1941-7.
28. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
29. Ru F, Surdenikova L, Brozmanova M, Kollarik M. Adenosine-induced activation of esophageal nociceptors. Am J Physiol Gastrointest Liver Physiol 2011; 300: G485-93.
30. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000; 275: 4429-34.
31. 3 adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem 2012; 55: 4847-60.
32. Yoon MH, Bae HB, Choi JI. Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test. Anesth Analg 2005; 101: 1417-21.
33. Zylka MJ. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 2011; 17: 188-96.